Clinical trial
A Single-center, Randomized, Double-blind, Phase IV Lot-to-lot Consistency Clinical Trial in 18-30 Years-old Females in China to Evaluate Immunogenicity and Safety of Recombinant Human Papillomavirus 9-valent (Types 6/11/16/18/31/33/45/52/58) Vaccine (Escherichia Coli)
NCT07668271 is registered in ClinicalTrials.gov with Xiamen Innovax Biotech Co., Ltd as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Single-center, Randomized, Double-blind, Phase IV Lot-to-lot Consistency Clinical Trial in 18-30 Years-old Females in China to Evaluate Immunogenicity and Safety of Recombinant Human Papillomavirus 9-valent (Types 6/11/16/18/31/33/45/52/58) Vaccine (Escherichia Coli)
- Lead sponsor
- Xiamen Innovax Biotech Co., Ltd
- Phase
- Phase 4
- Overall status
- Recruiting
- Start date
- May 26, 2026
- Completion date
- February 28, 2027
- Enrollment
- 720 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
infection by human papilloma virus